Previous 10 | Next 10 |
While it's true that from an investing standpoint "slow and steady" wins the race, that doesn't mean you should avoid the many high-growth opportunities on the market right now. As investors look forward to a new year, a number of companies are poised to gain significantly in 2020 and beyond. T...
While it might be tempting to make one large $10,000 investment on your favorite stock, a smarter approach is to invest like a venture capitalist. Don't be afraid of volatile, high-growth stocks . But do spread your risk out among several investments. One or more might be a loser, but you'll mo...
Amarin (NASDAQ: AMRN ) resumed with Neutral rating and $22 (5% upside) price target at JPMorgan. Shares down 2% premarket. More news on: Amarin Corporation plc, Glaukos Corporation, Galapagos NV, Healthcare stocks news, Stocks on the move, , Read more ...
We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) announced today that John F. Thero, Amarin's president and chief executive officer, is scheduled to present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, CA...
Aimmune Therapeutics, Inc. (AIMT) has been quite a sprightly stock lately, and it has a couple of key events coming up as well. However, the firm also faces a few obstacles, the foremost being the FDA's stepmotherly attitude over the years. Its lead drug candidate Palforzia was approved by t...
In the world of biotech and pharma, the JP Morgan Healthcare Conference serves as an unofficial annual kick-off event. Industry leaders, investors, analysts, and investment bankers overrun Union Square in San Francisco as they attempt to garner a few precious minutes of face-to-face time ...
Amarin ( AMRN ) has been re-defining the omega-3 market with last year's REDUCE-IT results, wherein they demonstrated that addition of Vascepa led to a 25% relative risk reduction in onset of first major cardiovascular event vs statin monotherapy. This was followed by a recent FDA label exp...
VASCEPA becomes the first and only Health Canada approved medication for reducing cardiovascular risk beyond cholesterol lowering therapy in the studied high-risk patients approved for treatment Commercial launch expected in mid-February 2020 by Amarin’s commercial par...
Amarin ( AMRN ) is fast approaching a significant event as the company’s lawsuit against a couple of generic drug makers is scheduled for trial on January 13, 2020. The main counter parties in this case are Dr. Reddy’s Laboratories (RDY), Hikma Pharmaceuticals (HKMPF) and Teva (T...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...